On this page
Multiple sulfatase deficiency
MSD is a severe, progressive disorder that typically affects multiple organ systems, including the brain, bones, and skin. It is caused by genetic changes that disrupt the activity of many different sulfatase enzymes, leading to a build-up of certain substances within cells.
Available at Jeen Health
Clinical tests that include this
Overview
Multiple sulfatase deficiency (MSD) is a very rare, inherited metabolic disorder. It is characterised by the reduced activity of at least ten different enzymes known as sulfatases [PMID:11967262]. These enzymes are responsible for breaking down specific complex molecules within cells. When sulfatases do not function correctly, these molecules accumulate, particularly within lysosomes - the 'recycling centres' of the cell. This build-up can lead to damage and dysfunction in various tissues and organs throughout the body.
MSD is considered a lysosomal storage disorder due to the accumulation of undigested materials in lysosomes. The condition is progressive, meaning symptoms tend to worsen over time. Although there is a spectrum of severity, MSD often presents with significant neurological involvement and affects multiple body systems.
Symptoms & clinical features
The symptoms of multiple sulfatase deficiency can vary significantly between individuals, but typically include developmental delay, seizures, and difficulties with movement. Children affected by MSD may initially appear healthy, but developmental milestones often begin to regress. Neurological symptoms are prominent and can include progressive intellectual disability and difficulties with speech and swallowing.
Physical signs can include coarse facial features, skeletal abnormalities (dysostosis multiplex), and distinctive skin changes, such as dry, scaly skin (ichthyosis) [PMID:33671239]. Vision and hearing may also be affected. In some cases, heart problems and enlargement of the liver and spleen (hepatosplenomegaly) have been observed. The age of onset and severity of these symptoms depend on the specific genetic change and the residual enzyme activity.
Video: Genetics 101
Affected organs
Multiple sulfatase deficiency can affect many different organs and body systems. The central nervous system, including the brain, is particularly vulnerable, leading to neurological problems and developmental delays. The skeletal system is also commonly affected, resulting in bone deformities and joint stiffness. The skin often shows signs of the condition, typically presenting as ichthyosis.
Other organs that may be involved include the eyes, leading to vision impairment, and the ears, potentially causing hearing loss. The liver and spleen may also be enlarged in some individuals. The wide range of affected organs reflects the widespread presence of sulfatase enzymes throughout the body and their crucial role in cellular metabolism.
Risks & severity
Multiple sulfatase deficiency is a severe and progressive condition. The severity and age of onset can vary, with more severe forms typically presenting earlier in infancy or early childhood and progressing more rapidly. Unfortunately, there is no cure for MSD, and the prognosis is generally poor, especially for individuals with severe neurological involvement.
Exact prevalence figures are not well established due to its extreme rarity. Life expectancy can be significantly reduced, particularly in severe cases where complications such as respiratory infections or neurological deterioration become life-threatening. The specific genetic variant in SUMF1 can influence the level of residual enzyme activity, which in turn correlates with the clinical severity and progression of the disease [PMID:11967262].
Genetic causes
Multiple sulfatase deficiency is caused by pathogenic variants in the SUMF1 gene (sulfatase modifying factor 1). The SUMF1 gene provides instructions for making a protein that is essential for the proper function of all sulfatase enzymes. This protein helps to activate sulfatases by modifying a specific amino acid within them.
When there is a pathogenic change in SUMF1, the protein it produces is either non-functional or has reduced activity. This leads to a widespread deficiency in the activity of multiple sulfatase enzymes, rather than just one. Without properly activated sulfatases, the complex molecules they normally break down accumulate in the lysosomes of cells, causing the wide range of symptoms seen in MSD.
- SUMF1 sulfatase modifying factor 1
Inheritance pattern
Multiple sulfatase deficiency has an autosomal recessive inheritance pattern. This means that a person must inherit two copies of the altered SUMF1 gene - one from each parent - to develop the condition.
Individuals who inherit only one copy of the altered gene are known as carriers. Carriers typically do not show any symptoms of MSD themselves because their one working copy of the gene is usually sufficient to produce enough functional SUMF1 protein. If both parents are carriers of a pathogenic variant in SUMF1, there is a 1 in 4 (25%) chance with each pregnancy that their child will inherit two altered copies and be affected by MSD, a 1 in 2 (50%) chance the child will be a carrier, and a 1 in 4 (25%) chance the child will inherit two working copies and not be affected or a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of multiple sulfatase deficiency typically begins with recognising the characteristic clinical symptoms. If MSD is suspected, biochemical tests can measure the activity of various sulfatase enzymes in blood or skin cell samples. A significant reduction in the activity of multiple sulfatases strongly suggests MSD.
Confirmation of the diagnosis involves genetic testing for pathogenic variants in the SUMF1 gene. This can be performed through the NHS Genomic Medicine Service (GMS), often following referral from a specialist paediatrician or clinical geneticist. The relevant NHS R-code for testing the SUMF1 gene would be used. This genetic testing can identify the specific changes in the gene, providing a definitive diagnosis and helping to guide future management and family planning.
Management & lifestyle
Currently, there is no specific cure for multiple sulfatase deficiency, and management primarily focuses on alleviating symptoms and providing supportive care. This involves a multidisciplinary approach, with care coordinated by various specialists, including neurologists, paediatricians, orthopaedics, and therapists.
Treatments may include anticonvulsant medications to manage seizures, physical and occupational therapy to help with movement and daily activities, and speech therapy for communication and feeding difficulties. Regular monitoring of neurological function, bone health, and other organ systems is important. Genetic counselling is a crucial part of the management, offering information about the condition, inheritance patterns, and support for families. Research into potential therapies, such as gene therapy, is ongoing.
UK care pathway
In the UK, individuals suspected of having a rare genetic condition like multiple sulfatase deficiency would typically be referred by their GP or a specialist to a clinical genetics service. This service can provide expert assessment, genetic counselling, and arrange for diagnostic genetic testing through the NHS Genomic Medicine Service (GMS). Genetic tests for conditions like MSD are listed under specific R-codes in the NHS National Genomic Test Directory. Genetic counsellors play a vital role in explaining the condition, its inheritance, and the implications for the wider family.
Frequently asked questions
What is the life expectancy for someone with multiple sulfatase deficiency?
Life expectancy for individuals with multiple sulfatase deficiency can vary, but it is generally reduced, especially in severe forms. The prognosis depends on the specific genetic change and the severity of symptoms, particularly neurological involvement. Supportive care aims to improve quality of life and manage complications.
Can multiple sulfatase deficiency be prevented?
As multiple sulfatase deficiency is an inherited genetic condition, it cannot be prevented. However, if there is a known family history, genetic counselling and prenatal diagnosis options may be available to prospective parents. Carrier testing can also be offered to identify individuals who carry one copy of the altered gene.
How common is multiple sulfatase deficiency?
Multiple sulfatase deficiency is considered a very rare condition. Its exact prevalence is not precisely known due to its rarity, but it affects only a small number of individuals worldwide. This rarity can sometimes make diagnosis challenging.
Are there any treatments that can cure multiple sulfatase deficiency?
Currently, there is no specific cure for multiple sulfatase deficiency. Treatment focuses on managing the symptoms and providing supportive care to improve the individual's quality of life. This includes therapies for neurological symptoms, physical therapy, and other medical interventions as needed. Research into potential new therapies is ongoing.
What is the role of the SUMF1 gene in multiple sulfatase deficiency?
The SUMF1 gene provides instructions for making a protein that is crucial for activating many different sulfatase enzymes. When there is a pathogenic variant in SUMF1, this activation process is impaired, leading to reduced activity of multiple sulfatases. This widespread enzyme deficiency causes the accumulation of substances in cells, resulting in the symptoms of MSD.
References
- Adam MP, Bick S, Mirzaa GM. Multiple Sulfatase Deficiency. 1993. PMID: 30896912
- Burlina AP, Manara R, Gueraldi D. Lysosomal storage diseases. Handbook of clinical neurology. 2024. PMID: 39322377
- Valayannopoulos V, Nicely H, Harmatz P. Mucopolysaccharidosis VI. Orphanet journal of rare diseases. 2010. PMID: 20385007
- Soong BW, Casamassima AC, Fink JK. Multiple sulfatase deficiency. Neurology. 1988. PMID: 2899861
- Schlotawa L, Adang LA, Radhakrishnan K. Multiple Sulfatase Deficiency: A Disease Comprising Mucopolysaccharidosis, Sphingolipidosis, and More Caused by a Defect in Posttranslational Modification. International journal of molecular sciences. 2020. PMID: 32414121
- Wood TC, Harvey K, Beck M. Diagnosing mucopolysaccharidosis IVA. Journal of inherited metabolic disease. 2013. PMID: 23371450
- Finglas A. View from inside: When multiple sulfatase deficiency changes everything about how you live and becomes your life. Journal of inherited metabolic disease. 2020. PMID: 32845037
- Diez-Roux G, Ballabio A. Sulfatases and human disease. Annual review of genomics and human genetics. 2005. PMID: 16124866